EA202192349A1 - Комбинации, пригодные в способе лечения саркомы - Google Patents

Комбинации, пригодные в способе лечения саркомы

Info

Publication number
EA202192349A1
EA202192349A1 EA202192349A EA202192349A EA202192349A1 EA 202192349 A1 EA202192349 A1 EA 202192349A1 EA 202192349 A EA202192349 A EA 202192349A EA 202192349 A EA202192349 A EA 202192349A EA 202192349 A1 EA202192349 A1 EA 202192349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sarcoma
subject
treatment
combinations suitable
administering
Prior art date
Application number
EA202192349A
Other languages
English (en)
Russian (ru)
Inventor
Марла Л. Уитолл
Лянсянь Цао
Джозефин Шиди
Роберт Спигел
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA202192349A1 publication Critical patent/EA202192349A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202192349A 2019-03-27 2020-03-27 Комбинации, пригодные в способе лечения саркомы EA202192349A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (1)

Publication Number Publication Date
EA202192349A1 true EA202192349A1 (ru) 2022-02-01

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192349A EA202192349A1 (ru) 2019-03-27 2020-03-27 Комбинации, пригодные в способе лечения саркомы

Country Status (11)

Country Link
US (1) US20220152024A1 (enExample)
EP (1) EP3947379A4 (enExample)
JP (1) JP7602481B2 (enExample)
CN (1) CN114096537B (enExample)
AU (1) AU2020248103A1 (enExample)
BR (1) BR112021019170A2 (enExample)
CA (1) CA3134648A1 (enExample)
EA (1) EA202192349A1 (enExample)
IL (1) IL286647A (enExample)
MX (1) MX2021011688A (enExample)
WO (1) WO2020198705A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
US20100297216A1 (en) * 2006-12-20 2010-11-25 Gabizon Alberto A Method for administration of pegylated liposomal doxorubicin
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
EA202192167A1 (ru) * 2019-03-11 2022-01-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Форма соединения, обладающая повышенной биодоступностью, и ее составы

Also Published As

Publication number Publication date
BR112021019170A2 (pt) 2022-03-03
US20220152024A1 (en) 2022-05-19
JP2022519930A (ja) 2022-03-25
MX2021011688A (es) 2022-01-24
CN114096537A (zh) 2022-02-25
EP3947379A1 (en) 2022-02-09
EP3947379A4 (en) 2022-12-21
JP7602481B2 (ja) 2024-12-18
CA3134648A1 (en) 2020-10-01
WO2020198705A1 (en) 2020-10-01
IL286647A (en) 2021-10-31
AU2020248103A1 (en) 2021-10-21
CN114096537B (zh) 2025-01-10

Similar Documents

Publication Publication Date Title
CY1125071T1 (el) Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
EA202190581A1 (ru) Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
EA201792287A1 (ru) Способы лечения рака
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202091881A1 (ru) Соединения для лечения боли
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
MX2022000811A (es) Inhibidores de enzimas.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2019001225A (es) Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
CY1125444T1 (el) Συνθεσεις εναντι μολυνσεων καντιντιασης
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
EA202192349A1 (ru) Комбинации, пригодные в способе лечения саркомы
EA202192117A1 (ru) Способ лечения множественной миеломы
ZA202102023B (en) Potentiation of helminth treatment